Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight loss drugs Mounjaro and Zepbound, in a matter of days. That’s because a federal judge has ruled that compounding pharmacies can’t keep making copies of the drug now that it’s no longer in shortage.

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now.

The FBI is warning the public about counterfeit compounded weight loss drugs on the market that claim to contain semaglutide, the active ingredient in Ozempic and Wegovy, two prescription medications used for weight loss.